Benzinga · Aug 11, 2026
HC Wainwright & Co. Maintains Buy on Agenus, Lowers Price Target to $25
HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and lowers the price target from $30 to $25.
AG
NASDAQ · AGEN
Agenus Inc.
Healthcare · Biotechnology
$7.00
Up+$0.10 (+1.45%)
Updated Aug 14, 2026, 7:25 AM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 113.25M
- P/E ratio
- -3.02
- Dividend yield
- 0.00%
- 52-week range
- $2.85 – $8.85
- Volume
- 624.95K
- Avg. volume
- 654.19K
Price performance
AGEN price history
1M range · 21 trading sessions · Daily adjusted prices
AGEN closed at $7.00 after 21 trading sessions, up 40.00% for the selected period.
- Last close
- $7.00
- Period change
- +40.00%
- Period low
- $4.97
- Period high
- $8.30
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $6.85 | $7.03 | $6.71 | $7.00 | 624.95K |
| Aug 12, 2026 | $6.91 | $7.20 | $6.83 | $6.90 | 1.15M |
| Aug 11, 2026 | $6.84 | $6.895 | $6.42 | $6.83 | 1.37M |
| Aug 10, 2026 | $6.83 | $7.09 | $6.36 | $7.00 | 1.92M |
| Aug 7, 2026 | $7.52 | $7.5497 | $6.92 | $6.96 | 1.19M |
| Aug 6, 2026 | $7.67 | $8.85 | $7.3228 | $7.49 | 2.46M |
| Aug 5, 2026 | $8.35 | $8.524 | $7.6901 | $7.78 | 1.46M |
| Aug 4, 2026 | $7.85 | $8.38 | $7.75 | $8.30 | 2.02M |
| Aug 3, 2026 | $7.65 | $8.09 | $7.50 | $7.82 | 1.65M |
| Jul 31, 2026 | $7.79 | $7.98 | $7.32 | $7.50 | 1.57M |
| Jul 30, 2026 | $6.77 | $7.99 | $6.51 | $7.91 | 3M |
| Jul 29, 2026 | $6.61 | $6.95 | $6.4835 | $6.63 | 1.86M |
| Jul 28, 2026 | $6.06 | $6.64 | $5.88 | $6.60 | 2.79M |
| Jul 27, 2026 | $5.99 | $6.20 | $5.87 | $6.13 | 1.23M |
| Jul 24, 2026 | $6.20 | $6.23 | $5.81 | $5.98 | 1.25M |
| Jul 23, 2026 | $5.53 | $6.225 | $5.46 | $6.19 | 2.33M |
| Jul 22, 2026 | $5.57 | $5.89 | $5.50 | $5.53 | 1.7M |
| Jul 21, 2026 | $5.00 | $5.90 | $4.99 | $5.58 | 2.6M |
| Jul 20, 2026 | $5.06 | $5.465 | $4.94 | $4.97 | 1.97M |
| Jul 17, 2026 | $4.91 | $5.1387 | $4.78 | $5.01 | 1.75M |
| Jul 16, 2026 | $5.00 | $5.28 | $4.67 | $5.00 | 2.7M |
Latest AGEN news
The latest Smart Investors Daily articles mentioning AGEN.
Stock researchCompany · Overview
AGEN research
Overview
Company profile and research snapshot.
Company profile
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $7.33
- Implied upside
- —
- Analysts
- 9
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 30, 2026 | B. Riley Securities | Buy | — |
| Jul 13, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 10, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 28, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Agenus Offers Up To 77,976,718 Shares Of Common Stock By Selling Securityholders
- Sec Filing
Benzinga · Aug 6, 2026
Agenus Q2 Sales $34.500M Beat $34.000M Estimate
Agenus (NASDAQ:AGEN) reported quarterly sales of $34.500 million which beat the analyst consensus estimate of $34.000 million by 1.47 percent. This is a 34.24 percent increase over sales of $25.700 million the same
Benzinga · Jul 30, 2026
B. Riley Securities Maintains Buy on Agenus, Raises Price Target to $14
B. Riley Securities analyst Mayank Mamtani maintains Agenus (NASDAQ:AGEN) with a Buy and raises the price target from $8 to $14.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
